Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RLAY Stock Summary
Top 10 Correlated ETFs
RLAY
In the News
3 Precision Medicine Stocks That Could Benefit From the Industry's Rise
Now might be a great time for investors to consider investing in precision medicine stocks. For those who don't know, precision medicine is an approach to disease treatment and prevention that tailors medical decisions to the individual patient.
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: TD Cowen's 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 a.m.
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024.
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The 7 Best Penny Stocks for 200% Returns
This year is going to offer a lot of opportunities for risk seeking investors. The world of penny stocks is well known to be speculative and is usually the domain of investors possessing a risk seeking profile.
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D.
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence
We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.
Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)
Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ample short-term liquidity and significant assets covering debts. Market sentiment is skeptical, with high short interest and the stock's underperformance relative to the S&P 500, but prominent institutions show confidence in the company's long-term prospects.
RLAY Financial details
RLAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 1.94 | 0.03 | 0.01 | 0 | |
Net income per share | -15.53 | -1.15 | -5.22 | -2.27 | 0 | |
Operating cash flow per share | -15.45 | -2.4 | -0.78 | -2.04 | 0 | |
Free cash flow per share | -17.32 | -2.45 | -0.82 | -2.13 | 0 | |
Cash per share | 83.11 | 15.91 | 17.2 | 16.45 | 0.01 | |
Book value per share | -42.15 | 17.91 | 9.44 | 8.47 | 0.01 | |
Tangible book value per share | -42.15 | 17.91 | 9.41 | 8.45 | 0.01 | |
Share holders equity per share | -42.15 | 17.91 | 9.44 | 8.47 | 0.01 | |
Interest debt per share | 5.8 | 0.57 | 0.24 | 0.44 | 0 | |
Market cap | 150.05M | 1.77B | 2.92B | 1.68B | 1349.57B | |
Enterprise value | 132.93M | 1.35B | 1.99B | 735.6M | 1349.48B | |
P/E ratio | -2.26 | -36.14 | -5.88 | -6.59 | -3.95K | |
Price to sales ratio | 0 | 21.43 | 964.56 | 1.21K | 52.83K | |
POCF ratio | -2.27 | -17.28 | -39.27 | -7.31 | -4.49K | |
PFCF ratio | -2.02 | -16.96 | -37.52 | -7.03 | -4.43K | |
P/B Ratio | -0.83 | 2.32 | 3.25 | 1.76 | 1.79K | |
PTB ratio | -0.83 | 2.32 | 3.25 | 1.76 | 1.79K | |
EV to sales | 0 | 16.31 | 655.82 | 532.65 | 52.83K | |
Enterprise value over EBITDA | -1.64 | -25.8 | -22.24 | -2.28 | -3.55K | |
EV to operating cash flow | -2.01 | -13.15 | -26.7 | -3.21 | -4.49K | |
EV to free cash flow | -1.79 | -12.91 | -25.51 | -3.08 | -4.43K | |
Earnings yield | -0.44 | -0.03 | -0.17 | -0.15 | 0 | |
Free cash flow yield | -0.49 | -0.06 | -0.03 | -0.14 | 0 | |
Debt to equity | -0.14 | 0.03 | 0.03 | 0.06 | 0.07 | |
Debt to assets | 0.06 | 0.03 | 0.02 | 0.05 | 0.06 | |
Net debt to EBITDA | 0.21 | 8.1 | 10.47 | 2.92 | 0.24 | |
Current ratio | 30.08 | 56.49 | 40.14 | 16 | 25.44 | |
Interest coverage | 0 | 0 | 0 | 34.14 | 0 | |
Income quality | 0.88 | 1.96 | 0.2 | 0.79 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.47 | 18.95 | 47.78 | 2.93 | |
Research and developement to revenue | 0 | 1.21 | 57 | 178.39 | 12.92 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.12 | 0.02 | 0.05 | 0.04 | 0.01 | |
Capex to revenue | 0 | -0.02 | -1.15 | -6.56 | -0.16 | |
Capex to depreciation | -2.81 | -0.54 | -0.88 | -2.19 | -0.78 | |
Stock based compensation to revenue | 0 | 0.39 | 16 | 40.65 | 3.37 | |
Graham number | 121.37 | 21.53 | 33.3 | 20.77 | 0.02 | |
ROIC | 0.57 | -0.06 | -0.53 | -0.25 | -0.39 | |
Return on tangible assets | -0.17 | -0.06 | -0.49 | -0.23 | -0.41 | |
Graham Net | -50.85 | 13.71 | 12.49 | 15.2 | 0.01 | |
Working capital | 348.55M | 756.47M | 951.92M | 955.8M | 739.83M | |
Tangible asset value | -180.44M | 763.29M | 895.51M | 947.92M | 749.7M | |
Net current asset value | -212.97M | 733.56M | 865.61M | 869.95M | 678.13M | |
Invested capital | -0.14 | 0.03 | 0.03 | 0.06 | 0.07 | |
Average receivables | 0 | 41.33M | 43.8M | 5.08M | 2.61M | |
Average payables | 5.85M | 6.67M | 7.31M | 9.43M | 9.89M | |
Average inventory | 0 | -119.03M | -460.28M | -335.19M | 6.06M | |
Days sales outstanding | 0 | 365 | 595.28 | 1.38K | 0 | |
Days payables outstanding | 896.91 | 653.17 | 769.62 | 934.86 | 638.07 | |
Days of inventory on hand | 0 | -24.48K | -63.47K | 1.07K | 0 | |
Receivables turnover | 0 | 1 | 0.61 | 0.26 | 0 | |
Payables turnover | 0.41 | 0.56 | 0.47 | 0.39 | 0.57 | |
Inventory turnover | 0 | -0.01 | -0.01 | 0.34 | 0 | |
ROE | 0.37 | -0.06 | -0.55 | -0.27 | -0.45 | |
Capex per share | -1.87 | -0.05 | -0.04 | -0.08 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.21 | 0 | |
Net income per share | -0.36 | -0.72 | -0.81 | -0.54 | 0 | |
Operating cash flow per share | -0.47 | -0.55 | -0.56 | -0.62 | 0 | |
Free cash flow per share | -0.49 | -0.57 | -0.58 | -0.62 | 0 | |
Cash per share | 15.26 | 7.73 | 7.16 | 6.63 | 0.01 | |
Book value per share | 7.86 | 7.28 | 6.66 | 6.37 | 0.01 | |
Tangible book value per share | 7.84 | 7.26 | 6.64 | 6.35 | 0.01 | |
Share holders equity per share | 7.86 | 7.28 | 6.66 | 6.37 | 0.01 | |
Interest debt per share | 0.45 | 0.41 | 0.46 | 0.45 | 0 | |
Market cap | 1.81B | 2B | 1.53B | 1.03B | 1349.57B | |
Enterprise value | 866.07M | 1.89B | 1.44B | 931.24M | 1349.48B | |
P/E ratio | -10.43 | -5.72 | -3.88 | -3.91 | -4.04K | |
Price to sales ratio | 7.14K | 8.84K | 12.84K | 40.79 | -1.35B | |
POCF ratio | -31.66 | -29.77 | -22.28 | -13.63 | -15.13K | |
PFCF ratio | -30.43 | -28.94 | -21.8 | -13.53 | -15.11K | |
P/B Ratio | 1.9 | 2.26 | 1.89 | 1.32 | 1.79K | |
PTB ratio | 1.9 | 2.26 | 1.89 | 1.32 | 1.79K | |
EV to sales | 3.42K | 8.38K | 12.09K | 36.95 | -1.35B | |
Enterprise value over EBITDA | -9.22 | -18.72 | -13.19 | -12.66 | -14.21K | |
EV to operating cash flow | -15.17 | -28.21 | -20.96 | -12.35 | -15.13K | |
EV to free cash flow | -14.58 | -27.43 | -20.51 | -12.26 | -15.11K | |
Earnings yield | -0.02 | -0.04 | -0.06 | -0.06 | 0 | |
Free cash flow yield | -0.03 | -0.03 | -0.05 | -0.07 | 0 | |
Debt to equity | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | |
Debt to assets | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | |
Net debt to EBITDA | 10.02 | 1.03 | 0.83 | 1.31 | 0.95 | |
Current ratio | 16 | 13.6 | 12.36 | 16.39 | 25.44 | |
Interest coverage | 21.34 | 14.58 | 0 | 0 | -13.29 | |
Income quality | 0.85 | 0.71 | 0.7 | 1.15 | 1.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 64.71 | 86.63 | 169.08 | 0.73 | -16.77K | |
Research and developement to revenue | 265.92 | 366.49 | 741.18 | 3.23 | -77.5K | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.03 | 0.02 | 0.01 | 0 | |
Capex to revenue | -9.15 | -8.47 | -12.63 | -0.02 | 118 | |
Capex to depreciation | -1.99 | -1.6 | -1.13 | -0.43 | -0.09 | |
Stock based compensation to revenue | 54.61 | 95.21 | 196.73 | 0.87 | -19.27K | |
Graham number | 7.96 | 10.86 | 11.01 | 8.78 | 0.01 | |
ROIC | -0.04 | -0.09 | -0.1 | -0.08 | -0.13 | |
Return on tangible assets | -0.04 | -0.08 | -0.1 | -0.07 | -0.1 | |
Graham Net | 14.11 | 6.54 | 5.95 | 5.65 | 0.01 | |
Working capital | 955.8M | 887.92M | 812.77M | 781.05M | 739.83M | |
Tangible asset value | 947.92M | 881.11M | 807.82M | 776.07M | 749.7M | |
Net current asset value | 869.95M | 804.24M | 732.45M | 703.21M | 678.13M | |
Invested capital | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | |
Average receivables | 5.17M | 5.23M | 2.65M | 144.5K | 105.5K | |
Average payables | 10.03M | 11.21M | 13.31M | 14.07M | 11.28M | |
Average inventory | 14.46M | 11.69M | 10.29M | 13.3M | 8.65M | |
Days sales outstanding | 1.86K | 2.08K | 58.99 | 0.75 | 0 | |
Days payables outstanding | 816.48 | 889.77 | 997.02 | 881.71 | 602.9 | |
Days of inventory on hand | 934.73 | 847.22 | 627.84 | 1.14K | 0 | |
Receivables turnover | 0.05 | 0.04 | 1.53 | 119.44 | 0 | |
Payables turnover | 0.11 | 0.1 | 0.09 | 0.1 | 0.15 | |
Inventory turnover | 0.1 | 0.11 | 0.14 | 0.08 | 0 | |
ROE | -0.05 | -0.1 | -0.12 | -0.08 | -0.11 | |
Capex per share | -0.02 | -0.02 | -0.01 | 0 | 0 |
RLAY Frequently Asked Questions
What is Relay Therapeutics, Inc. stock symbol ?
Relay Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol RLAY
Is Relay Therapeutics, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $22.83. The lowest prediction is $12.5 and the highest is $33
What is RLAY stock prediction ?
What is Relay Therapeutics, Inc. stock quote today ?
Relay Therapeutics, Inc. stock price is $8.16 today.
Is Relay Therapeutics, Inc. stock public?
Yes, Relay Therapeutics, Inc. is a publicly traded company.